Form 4: Kathleen LaPorte, Director at 89bio, Inc., Reports Stock Option Grant

Director Kathleen LaPorte reports the acquisition of stock options for 56,400 shares of 89bio, Inc. common stock.

Summary

• Kathleen LaPorte, a director at 89bio, Inc., filed a Form 4 with the SEC.
• The report details the grant of stock options to LaPorte on February 3, 2025.
• The options give LaPorte the right to purchase 56,400 shares of 89bio, Inc.'s common stock at an exercise price of $9.60 per share.
• The options will vest in full on February 1, 2026, contingent upon LaPorte's continued service to the company.
• The options expire on February 3, 2035.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to stock option grants, which is generally neutral in sentiment. It indicates confidence in the company's future, but it's not overwhelmingly positive or negative.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of compensation for directors and executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's performance.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates